Manufacturer of Controlled Substances; Notice of Registration, 22146-22147 [2011-9611]

Download as PDF 22146 Federal Register / Vol. 76, No. 76 / Wednesday, April 20, 2011 / Notices named as respondents Astra Tobacco Corporation of Chapel Hill, North Carolina; delfortgroup AG of Traun, Austria; LIPtec GmbH and Julius Glatz GmbH of Neidenfels, Germany. On March 22, 2011, the ALJ issued an ID (Order No. 5) granting complainant Schweitzer’s motion to amend the complaint and notice of the investigation to add seven additional respondents to the investigation. The new respondents are Dosal Tobacco Corp.; Farmer’s Tobacco Co.; S&M Brands, Inc.; Tantus Tobacco, LLC; KneX Worldwide, LLC; Dr. Franz Feurstein GmbH; and PapierfabrikWattens GmbH & Co. KG. No party petitioned for review of the subject ID. The Commission has determined not to review the ID. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in section 210.42(h) of the Commission’s Rules of Practice and Procedure (19 CFR 210.42(h)). By order of the Commission: Issued: April 18, 2011. William R. Bishop, Hearings and Meetings Coordinator. By order of the Commission. Issued: April 15, 2011. James R. Holbein, Acting Secretary to the Commission. Cocaine (9041) .............................. Ecgonine (9180) ............................ [FR Doc. 2011–9584 Filed 4–19–11; 8:45 am] BILLING CODE 7020–02–P INTERNATIONAL TRADE COMMISSION [USITC SE–11–010] Government in the Sunshine Act Meeting Notice United States International Trade Commission. TIME AND DATE: April 28, 2011 at 11 a.m. PLACE: Room 110, 500 E Street SW., Washington, DC 20436, Telephone: (202) 205–2000. STATUS: Open to the public. MATTERS TO BE CONSIDERED: 1. Agendas for future meetings: none. 2. Minutes. 3. Ratification List. 4. Vote in Inv. Nos. 701–TA–475 and 731–TA–1177 (Final) (Aluminum Extrusions from China). The Commission is currently scheduled to transmit its determinations and Commissioners’ opinions to the Secretary of Commerce on or before May 13, 2011. 5. Outstanding action jackets: none. In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting. Earlier Notification of this meeting was not possible. srobinson on DSKHWCL6B1PROD with NOTICES AGENCY HOLDING THE MEETING: VerDate Mar<15>2010 17:52 Apr 19, 2011 Jkt 223001 Drug Enforcement Administration (DEA) as a bulk manufacturer of the following basic classes of controlled substances: [FR Doc. 2011–9726 Filed 4–18–11; 4:15 pm] Drug BILLING CODE 7020–02–P Amphetamine (1100) .................... Phenylacetone (8501) .................. Schedule II II DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 24, 2011, Stepan Company, Natural Products Dept., 100 W. Hunter Avenue, Maywood, New Jersey 07607, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than June 20, 2011. Dated: April 13, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than June 20, 2011. Dated: April 13, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2011–9610 Filed 4–19–11; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated June 17, 2010, and published in the Federal Register on June 28, 2010, 75 FR 36679, Lin Zhi International Inc., 670 Almanor Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: [FR Doc. 2011–9619 Filed 4–19–11; 8:45 am] Drug Schedule BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 3, 2010, Noramco Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801– 4485, made application by letter to the PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 Tetrahydrocannabinols (7370) ..... 3,4Methylenedioxymethamphetamine (MDMA) (7405). Cocaine (9041) ............................. Oxycodone (9143) ........................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... I I II II II II II II The company plans to manufacture the listed controlled substances as bulk reagents for use in drug abuse testing. E:\FR\FM\20APN1.SGM 20APN1 Federal Register / Vol. 76, No. 76 / Wednesday, April 20, 2011 / Notices No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Lin Zhi International Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Lin Zhi International Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with State and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: April 13, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2011–9611 Filed 4–19–11; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances Notice of Registration By Notice dated August 2, 2010, and published in the Federal Register on September 1, 2010, (75 FR 53721), Chattem Chemicals Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: srobinson on DSKHWCL6B1PROD with NOTICES Drug Schedule 4–Methoxyamphetamine (7411) ... Dihydromorphine (9145) ............... Amphetamine (1100) .................... Methamphetamine (1105) ............ Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Pentobarbital (2270) ..................... Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Meperidine (9230) ........................ Methadone (9250) ........................ Methadone intermediate (9254) ... Morphine (9300) ........................... Oripavine (9330) ........................... Thebaine (9333) ........................... VerDate Mar<15>2010 17:52 Apr 19, 2011 I I II II II II II II II II II II II II II II II II Jkt 223001 Drug Schedule Oxymorphone (9652) ................... Noroxymorphone (9668) .............. Alfentanil (9737) ........................... Reminfentanil (9739) .................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Chattem Chemicals Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Chattem Chemicals Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: April 13, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2011–9620 Filed 4–19–11; 8:45 am] BILLING CODE 4410–09–P FOREIGN CLAIMS SETTLEMENT COMMISSION [F.C.S.C. Meeting Notice No. 2–11] Sunshine Act Meeting The Foreign Claims Settlement Commission, pursuant to its regulations (45 CFR part 504) and the Government in the Sunshine Act (5 U.S.C. 552b), hereby gives notice in regard to the scheduling of meetings for the transaction of Commission business and other matters specified, as follows: Date and Time: Tuesday, May 10, 2011, at 10 a.m. Subject Matter: Issuance of Proposed Decisions in claims against Albania and Libya. Status: Open. All meetings are held at the Foreign Claims Settlement Commission, 600 E Street, NW., Washington, DC. Requests for information, or advance notices of intention to observe an open meeting, PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 22147 may be directed to: Executive Officer, Foreign Claims Settlement Commission, 600 E Street, NW., Room 6002, Washington, DC 20579. Telephone: (202) 616–6975. Judith H. Lock, Executive Officer. [FR Doc. 2011–9682 Filed 4–18–11; 4:15 pm] BILLING CODE 6770–01–P DEPARTMENT OF LABOR Employment & Training Administration [SGA–DFA–PY–10–03] Solicitation for Grant Applications (SGA); Trade Adjustment Assistance Community College and Career Training Grants Program; Amendment Three Employment and Training Administration (ETA), Labor. ACTION: Notice: Amendment to SGA/ DFA PY 10–03. AGENCY: The Employment and Training Administration published a notice in the Federal Register on January 21, 2011, announcing the availability of funds and Solicitation for Grant Applications (SGA) for the Trade Adjustment Assistance Community College and Career Training grant program (TAACCCT) to be awarded through a competitive process. This amendment to the SGA clarifies items related to making portions of grant applications publicly available. The document is hereby amended. In Section IIIG3, of the solicitation (https://www.doleta.gov/grants/pdf/ SGA–DFA–PY–10–03.pdf), the following text should be replaced: Old Text—‘‘The Department is committed to conducting a transparent grant award process and publicizing information about program outcomes. Applicants are advised their application and information related to its review and evaluation (whether or not the application is successful) may be made publicly available, either fully or partially. In addition, information about grant progress and results may also be made publicly available.’’ New Text—‘‘The Department is committed to conducting a transparent grant application and award process. Among other things, posting grant applications on public Web sites is a means of promoting and sharing innovative ideas. For this grant competition, we will publish the Technical Proposal required by Section IVB, Part II for all those applications that are awarded grants, on the SUMMARY: E:\FR\FM\20APN1.SGM 20APN1

Agencies

[Federal Register Volume 76, Number 76 (Wednesday, April 20, 2011)]
[Notices]
[Pages 22146-22147]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-9611]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated June 17, 2010, and published in the Federal 
Register on June 28, 2010, 75 FR 36679, Lin Zhi International Inc., 670 
Almanor Avenue, Sunnyvale, California 94085, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as a bulk manufacturer of the basic classes of controlled substances 
listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)...............  I
3,4-Methylenedioxymethamphetamine (MDMA)     I
 (7405).
Cocaine (9041).............................  II
Oxycodone (9143)...........................  II
Hydrocodone (9193).........................  II
Methadone (9250)...........................  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
as bulk reagents for use in drug abuse testing.

[[Page 22147]]

    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Lin Zhi International Inc., to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated Lin Zhi International Inc., to ensure that 
the company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with State and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 
21 CFR 1301.33, the above named company is granted registration as a 
bulk manufacturer of the basic classes of controlled substances listed.

    Dated: April 13, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2011-9611 Filed 4-19-11; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.